Effects of DL-endopeptidase Producing Probiotics on Human Intestinal NOD2 Ligands and Related Functions

Early Phase 1Active Not RecruitingNCT06716047

Zhujiang Hospital30 enrolled

Overview

We have discovered a type of probiotic that can target activating intestinal NOD2, which is related to a series of human health issues.

This trial requires the subjects to take probiotics for a certain period of time, and we will collect blood, stool and questionnaires for subsequent testing, efficacy evaluation and safety evaluation.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

OTHER

Masking

SINGLE

Enrollment

Conditions

Microecological Therapy Probiotic Intervention

Interventions

Oral administrationOTHER

Take it directly

Eligibility

Sex: ALLHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Tend to participate the trial * Willing to provide written informed consent Exclusion Criteria: * Recent use of probiotics, antibiotics, laxatives, or gastrointestinal ulcer medications within the past month. * Gastrointestinal symptoms (e.g., constipation, abdominal pain, diarrhea, melena, hematochezia) in the past month. * Other conditions considered by researchers for exclusion

Locations (1)

Industrial Avenue 253, canton

Guangzhou, Guangzhou, China

Outcomes

Primary Outcomes

safty

Adverse reaction by questionnaire survey

Time frame: up to 2 weeks

NOD2 activation level

the level of NOD2 activation by fecal in vitro experiments

Time frame: up to 2 weeks

Secondary Outcomes

Intestinal barrier

Intestinal Barrier markers

Time frame: up to 2 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.